Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies

Infection and Immunity

Volumn 78, Issue 2, 2010, Pages 802-809

  Hellerud, Bernt Christian ^a,b   Aase, Audun ^c   Herstad, Tove Karin ^c   Næss, Lisbeth Meyer ^c   Kristiansen, Lisa Høyem ^a   Trøseid, Anne Marie Siebke ^b   Harboe, Morten ^a   Lappegård, Knut Tore ^d,e   Brandtzæg, Petter ^b   Høiby, E Arne ^c   Mollnes, Tom Eirik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d NORDLAND HOSPITAL   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIUM ANTIBODY; CD11B ANTIGEN; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C5; DNA; MANNOSE BINDING LECTIN; OPSONIN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD; CASE REPORT; CELL PROLIFERATION; COLONY FORMING UNIT; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GRANULOCYTE; HEATING; HOST RESISTANCE; HUMAN; HUMAN CELL; MALE; NEISSERIA MENINGITIDIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SERUM; SERUM BACTERICIDAL ACTIVITY; VACCINATION;

EID: 76749166634     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01044-09     Document Type: Article

References (48)

1. Aase, A., G. Bjune, E. A. Hoiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536.
2. Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Hoiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunizations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21:2042-2051.
3. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Hoiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976.
4. Brouwer, M. C., J. de Gans, S. G. Heckenberg, A. H. Zwinderman, T. van der Poll, and D. van de Beek. 2009. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 9:31-44.
5. Caugant, D. A., and M. C. Maiden. 2009. Meningococcal carriage and disease-population biology and evolution. Vaccine 27(Suppl. 2):B64-B70.
6. de Vries, F. P., A. van der Ende, J. P. van Putten, and J. Dankert. 1996. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect. Immun. 64:2998-3006.
7. Drogari-Apiranthitou, M., C. A. Fijen, S. Thiel, A. Platonov, L. Jensen, J. Dankert, and E. J. Kuijper. 1997. The effect of mannan-binding lectin on opsonophagocytosis of Neisseria meningitidis. Immunopharmacology 38:93-99.
8. Eisen, D. P., and R. M. Minchinton. 2003. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37:1496-1505.
9. Emonts, M., J. A. Hazelzet, R. de Groot, and P. W. Hermans. 2003. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3:565-577.
10. Estabrook, M. M., D. L. Jack, N. J. Klein, and G. A. Jarvis. 2004. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J. Immunol. 172:3784-3792.
11. Faber, J., T. Schuessler, A. Finn, C. Murdoch, W. Zenz, P. Habermehl, C. U. Meyer, B. U. Zabel, H. Schmitt, F. Zepp, and M. Knuf. 2007. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr. Infect. Dis. J. 26:243-246.
12. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
13. Fijen, C. A., E. J. Kuijper, M. T. te Bulte, M. R. Daha, and J. Dankert. 1999. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin. Infect. Dis. 28:98-105.
14. Frasch, C. E., R. Borrow, and J. Donnelly. 2009. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27:B112-B116.
15. Garred, P., T. E. Michaelsen, G. Bjune, S. Thiel, and A. Svejgaard. 1993. A low serum concentration of mannan-binding protein is not associated with serogroup B or C meningococcal disease. Scand. J. Immunol. 37:468-470.
16. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
17. Granoff, D. M. 2009. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 27(Suppl. 2):B117-B125.
18. Harboe, M., and T. E. Mollnes. 2008. The alternative complement pathway revisited. J. Cell Mol. Med. 12:1074-1084.
19. Hibberd, M. L., M. Sumiya, J. A. Summerfield, R. Booy, and M. Levin. 1999. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 353:1049-1053.
20. Holst, J., B. Feiring, J. E. Fuglesang, E. A. Hoiby, H. Nokleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734-737.
21. Jack, D. L., A. W. Dodds, N. Anwar, C. A. Ison, A. Law, M. Frosch, M. W. Turner, and N. J. Klein. 1998. Activation of complement by mannosebinding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J. Immunol. 160:1346-1353.
22. Jack, D. L., N. J. Klein, and M. W. Turner. 2001. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol. Rev. 180:86-99.
23. Jack, D. L., R. C. Read, A. J. Tenner, M. Frosch, M. W. Turner, and N. J. Klein. 2001. Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J. Infect. Dis. 184:1152-1162.
24. Jarvis, G. A., and N. A. Vedros. 1987. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect. Immun. 55:174-180.
25. Jonsson, G., L. Truedsson, G. Sturfelt, V. A. Oxelius, J. H. Braconier, and A. G. Sjoholm. 2005. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine 84:23-34.
26. Kemper, C., and D. E. Hourcade. 2008. Properdin: new roles in pattern recognition and target clearance. Mol. Immunol. 45:4048-4056.
27. Knutzen Steuer, K. L., L. B. Sloan, T. J. Oglesby, T. C. Farries, M. W. Nickells, P. Densen, J. B. Harley, and J. P. Atkinson. 1989. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement. J. Immunol. 143:2256-2261.
28. Kugelberg, E., B. Gollan, and C. M. Tang. 2008. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 26(Suppl. 8):I34-I39.
29. Lappegard, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, E. A. Hoiby, L. Schejbel, P. Garred, J. D. Lambris, M. Harboe, and T. E. Mollnes. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. U. S. A. 106:15861-15866.
30. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris. 2002. Essential role of the C5a receptor in Escherichia coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100:1869-1877.
31. Mollnes, T. E., P. Garred, and G. Bergseth. 1988. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin. Exp. Immunol. 73:484-488.
32. Ovstebo, R., P. Brandtzaeg, B. Brusletto, K. B. Haug, K. Lande, E. A. Hoiby, and P. Kierulf. 2004. Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J. Clin. Microbiol. 42:2980-2987.
33. Platonov, A. E., I. V. Vershinina, E. J. Kuijper, R. Borrow, and H. Kayhty. 2003. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21:4437-4447.
34. Plested, J. S., and D. M. Granoff. 2008. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin. Vaccine Immunol. 15:799-804.
35. Rosenqvist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
36. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
37. Sandbu, S., B. Feiring, P. Oster, O. S. Helland, H. S. Bakke, L. M. Naess, A. Aase, I. S. Aaberge, A. C. Kristoffersen, K. M. Rydland, S. Tilman, H. Nokleby, and E. Rosenqvist. 2007. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin. Vaccine Immunol. 14:1062-1069.
38. Schneider, M. C., R. M. Exley, H. Chan, I. Feavers, Y. H. Kang, R. B. Sim, and C. M. Tang. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575.
39. Schneider, M. C., R. M. Exley, S. Ram, R. B. Sim, and C. M. Tang. 2007. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol. 15:233-240.
40. Selander, B., U. Martensson, A. Weintraub, E. Holmstrom, M. Matsushita, S. Thiel, J. C. Jensenius, L. Truedsson, and A. G. Sjoholm. 2006. Mannanbinding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 116:1425-1434.
41. Sjoholm, A. G., G. Jonsson, J. H. Braconier, G. Sturfelt, and L. Truedsson. 2006. Complement deficiency and disease: an update. Mol. Immunol. 43:78-85.
42. Sprong, T., P. Brandtzaeg, M. Fung, A. M. Pharo, E. A. Hoiby, T. E. Michaelsen, A. Aase, J. W. van der Meer, M. van Deuren, and T. E. Mollnes. 2003. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102:3702-3710.
43. Sprong, T., D. Roos, C. Weemaes, C. Neeleman, C. L. Geesing, T. E. Mollnes, and M. van Deuren. 2006. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 107:4865-4870.
44. Stephens, D. S., B. Greenwood, and P. Brandtzaeg. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210.
45. Tully, J., R. M. Viner, P. G. Coen, J. M. Stuart, M. Zambon, C. Peckham, C. Booth, N. Klein, E. Kaczmarski, and R. Booy. 2006. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ 332:445-450.
46. van Emmerik, L. C., E. J. Kuijper, C. A. Fijen, J. Dankert, and S. Thiel. 1994. Binding of mannan-binding protein to various bacterial pathogens of meningitis. Clin. Exp. Immunol. 97:411-416.
47. Welsch, J. A., and D. Granoff. 2007. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin. Vaccine Immunol. 14:1596-1602.
48. Welsch, J. A., S. Ram, O. Koeberling, and D. M. Granoff. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.